Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, will release its Q2 2025 financial results on Thursday, August 7, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern time. Participants must pre-register to receive dial-in details and are encouraged to join 15 minutes before the start time. A live webcast will be available on Lisata's website, with a 12-month replay option.
Lisata Therapeutics (Nasdaq: LSTA), un'azienda farmaceutica in fase clinica specializzata nello sviluppo di terapie per tumori solidi avanzati e malattie gravi, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 giovedì 7 agosto 2025, dopo la chiusura del mercato.
L'azienda terrà una conference call alle 16:30 ora orientale. I partecipanti devono registrarsi in anticipo per ricevere i dettagli per la chiamata e sono invitati a collegarsi 15 minuti prima dell'inizio. Sarà disponibile una diretta web sul sito di Lisata, con la possibilità di riascolto per 12 mesi.
Lisata Therapeutics (Nasdaq: LSTA), una empresa farmacéutica en etapa clínica enfocada en desarrollar terapias para tumores sólidos avanzados y enfermedades graves, publicará sus resultados financieros del segundo trimestre de 2025 el jueves 7 de agosto de 2025, después del cierre del mercado.
La compañía realizará una conferencia telefónica a las 4:30 p.m., hora del este. Los participantes deben registrarse previamente para recibir los detalles de acceso y se recomienda unirse 15 minutos antes del inicio. Habrá una transmisión en vivo disponible en el sitio web de Lisata, con opción de reproducción durante 12 meses.
Lisata Therapeutics (나스닥: LSTA)는 진행성 고형암 및 중증 질환 치료제 개발에 주력하는 임상 단계 제약회사로, 2025년 8월 7일 목요일, 장 마감 후 2025년 2분기 재무 실적을 발표할 예정입니다.
회사는 동부 표준시 기준 오후 4시 30분에 콘퍼런스 콜을 진행합니다. 참가자는 사전 등록을 통해 전화 접속 정보를 받아야 하며, 시작 15분 전까지 접속할 것을 권장합니다. Lisata 웹사이트에서 생중계가 제공되며, 12개월간 다시보기 서비스도 이용할 수 있습니다.
Lisata Therapeutics (Nasdaq : LSTA), une société pharmaceutique en phase clinique spécialisée dans le développement de thérapies pour les tumeurs solides avancées et les maladies graves, publiera ses résultats financiers du deuxième trimestre 2025 le jeudi 7 août 2025, après la clôture du marché.
La société organisera une conférence téléphonique à 16h30 heure de l’Est. Les participants doivent s’inscrire à l’avance pour recevoir les informations de connexion et sont invités à se connecter 15 minutes avant le début. Une diffusion en direct sera disponible sur le site de Lisata, avec une option de replay pendant 12 mois.
Lisata Therapeutics (Nasdaq: LSTA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Therapien für fortgeschrittene solide Tumoren und schwere Erkrankungen spezialisiert hat, wird seine Finanzergebnisse für das zweite Quartal 2025 am Donnerstag, den 7. August 2025 nach Börsenschluss veröffentlichen.
Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten. Teilnehmer müssen sich im Voraus registrieren, um die Einwahldaten zu erhalten, und werden gebeten, 15 Minuten vor Beginn beizutreten. Ein Live-Webcast wird auf der Website von Lisata verfügbar sein, mit einer 12-monatigen Wiedergabemöglichkeit.
- None.
- None.
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the fourth quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For a comprehensive overview of certepetide's mechanism of action, please view our informative short film. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Lisata Therapeutics (LSTA) report Q2 2025 earnings?
What time is Lisata Therapeutics' Q2 2025 earnings call?
How can I access Lisata Therapeutics' Q2 2025 earnings call?
How long will Lisata Therapeutics' Q2 2025 earnings call replay be available?
